Status:
ACTIVE_NOT_RECRUITING
Compare Clinical Outcomes Between Advanced Immunotherapy and Classical Immunochemotherapy in RRMM
Lead Sponsor:
Seoul St. Mary's Hospital
Conditions:
Myeloma Multiple
Eligibility:
All Genders
19+ years
Brief Summary
\[Purpose\] This study aims to assess the efficacy of immunotherapeutic agents in real clinical settings by comparing the treatment outcomes of relapsed/refractory multiple myeloma patients treated w...
Eligibility Criteria
Inclusion
- Patients diagnosed with multiple myeloma at Seoul St. Mary's Hospital, Yeouido St. Mary's Hospital, Incheon St. Mary's Hospital, and Eunpyeong St. Mary's Hospital from May 2009 to June 2023.
- Age 19 and above.
- Patients who have undergone immunotherapy\* for the purpose of treating relapsed/refractory multiple myeloma.
- Immunotherapy is defined as one of the following drugs depending on the treatment timeline:
- Proteasome inhibitor, immune modulatory drug, monoclonal antibody, Chimeric Antigen Receptor T-cell therapy (CAR-T), bispecific antibody, antibody-drug conjugate.
Exclusion
- Patients diagnosed with conditions other than monoclonal gammopathy of undetermined significance (MGUS) or multiple myeloma.
Key Trial Info
Start Date :
September 25 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
1600 Patients enrolled
Trial Details
Trial ID
NCT06205823
Start Date
September 25 2023
End Date
December 31 2025
Last Update
January 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul St. Mary's Hospital, The Catholic University of Korea
Seoul, South Korea, 06591